alexion beat expect full steam ahead
ultomiri convers neurolog push
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research apr
estim
price data apr
rate updat apr
currenc amount express
methodolog valu compani
alexion report solid quarter revenu adjust
earn per share ahead expect
manag rais guidanc slightli effort convert
patient soliri
approach patent
expir ultomiri approv
januari well underway soliri launch
gener myasthenia gravi gmg continu drive
growth may adjust near-term estim
slightli expect materi chang fair valu
estim per share continu believ
market underappreci intang asset
behind alexion portfolio rare diseas narrow
first-quart revenu billion repres
growth last year driven soliri newli launch
ultomiri complement-medi diseas strensiq
kanuma rare metabol disord perform line
expect soliri driven
volum growth slightli off-set expect price
currenc headwind full year model high-single-
digit volum growth paroxysm nocturn hemoglobinuria
pnh atyp hemolyt urem syndrom ahu
strong uptak gmg compani report
gmg patient soliri mid-april slightli ahead
expect strong top-lin growth help boost
adjust oper margin basi point
oper expens project
first quarter anticip much chang
full-year outlook given sever trial pick
back half slightli later
mani trial ultomiri
approv pnh expect garner sever approv
come year alexion continu strategi
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
analyst note adjust net incom includ adjust differ non-gaap share
special develop market drug
rare life-threaten medic condit blockbust product soliri
approv paroxysm nocturn hemoglobinuria atyp hemolyt
urem syndrom gener myasthenia gravi next-gener
ultomiri recent approv paroxysm nocturn hemoglobinuria
strensiq kanuma target ultrarar metabol diseas alexion
rare diseas high unmet need
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
line model
main catalyst year alexion progress
soliri nmosd would strengthen posit
neurolog expect detail phase data soliri
nmosd may follow posit top-lin result last
septemb well potenti approv late june
like see strong launch nmosd later year
approv would indic compani
progress shift ultra-rar indic rare
indic larger target popul strong price
power given nmosd character
relaps altern off-label treatment
strong launch would testament compani
commerci strategi potenti challeng
convert patient soliri ultomiri manag
report compani file approv ultomiri
ahu put track launch
approv also model launch gmg
late-stag trial alreadi underway neuromyel
optica spectrum disord nmosd late-stag trial
plan late compani also recent
amyotroph later sclerosi al primari progress
multipl sclerosi ppm opportun earli
model especi given challeng neurolog
disord
ultomiri contribut million revenu first
quarter slightli expect still healthi
indic convers effort compani cite
pnh patient alreadi ultomiri treatment
sizabl progress toward compani goal
convers end expect convers
momentum slow throughout year effort
move earli adopt approv
subcutan dose instead intraven would
import boon compani hit efficaci
conveni late-stag trial subcutan ultomiri
underway pnh ahu expect
launch leav room potenti brand
earlier month first biosimilar soliri
approv russia anticip signific
impact outsid russia commonwealth
europ call manag state russian
biosimilar approv anticip alreadi
incorpor previou guidanc manag
surmis biosimilar current phase
trial would take three year enter market
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
